Literature DB >> 18056154

The influence of levosimendan and iloprost on renal ischemia-reperfusion: an experimental study.

Necmettin Yakut1, Haydar Yasa, Banu Bahriye Lafci, Ragip Ortac, Engin Tulukoglu, Murat Aksun, Cengiz Ozbek, Ali Gurbuz.   

Abstract

The effects of iloprost on ischemia-reperfusion injury have been studied on the skeletal, muscle, liver, myocardium, kidney, and spinal cord. However, no sufficient data exist about effects of levosimendan on renal ischemia-reperfusion injury. The purpose of this experimental study was to investigate and compare effectiveness of levosimendan and iloprost on renal injury induced by ischemia and reperfusion. Fifty rabbits were divided into five groups. Levosimendan was continuously infused starting half an hour before the cross-clamp. Cross-clamp time was one hour. After one hour ischemia, levosimendan was continued for 4 h in Group A whereas Group B took iloprost in the same protocol. Group C was the control group which did not receive any medication. Group D was sham group and Group E was medicated both iloprost and levosimendan. Renal tissues were histologically and biochemically evaluated. The histological scores were obtained according to presence of tubular necrosis and atrophy, regenerative atypia, hydropic degeneration (Group A vs. Group C<0.001, Group B vs. Group C<0.001, Group D vs. Group C<0.01, Group E vs. Group C<0.001). Mean malondialdehyde levels were 114+/-12 nmol/g tissue; in Group A 121+/-13 nmol/g tissue, in Group B 134+/-13 nmol/g tissue, in Group E 130+/-11 nmol/g tissue, in Group D 134+/-11 nmol/g tissue (Group A vs. Group B; P=0.003, Group B vs. Group D; P=0.132, Group A vs. Group E; P=0.132). Malondialdehyde levels and histologic scores of all of the groups were significantly different from the control group. Iloprost and pentoxyfillin reduced renal ischemia-reperfusion injury in rabbit model. There was no significant difference between these two medications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18056154     DOI: 10.1510/icvts.2007.161356

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  12 in total

1.  Treprostinil, a prostacyclin analog, ameliorates renal ischemia-reperfusion injury: preclinical studies in a rat model of acute kidney injury.

Authors:  Meiwen Ding; Evelyn Tolbert; Mark Birkenbach; Fatemeh Akhlaghi; Reginald Gohh; Nisanne S Ghonem
Journal:  Nephrol Dial Transplant       Date:  2021-01-25       Impact factor: 5.992

2.  Beneficial impact of levosimendan in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials.

Authors:  Tiziana Bove; Andrea Matteazzi; Alessandro Belletti; Gianluca Paternoster; Omar Saleh; Daiana Taddeo; Roberto Dossi; Teresa Greco; Nikola Bradic; Ino Husedzinovic; Caetano Nigro Neto; Vladimir V Lomivorotov; Maria Grazia Calabrò
Journal:  Heart Lung Vessel       Date:  2015

3.  Early administration of levosimendan is associated with improved kidney function after cardiac surgery - a retrospective analysis.

Authors:  Felix Balzer; Sascha Treskatsch; Claudia Spies; Michael Sander; Mark Kastrup; Herko Grubitzsch; Klaus-Dieter Wernecke; Jan P Braun
Journal:  J Cardiothorac Surg       Date:  2014-11-18       Impact factor: 1.637

4.  The effect of iloprost and N-acetylcysteine on skeletal muscle injury in an acute aortic ischemia-reperfusion model: an experimental study.

Authors:  Osman Tiryakioglu; Kamuran Erkoc; Bulent Tunerir; Onur Uysal; H Firat Altin; Tevfik Gunes; Selim Aydin
Journal:  Biomed Res Int       Date:  2015-03-05       Impact factor: 3.411

5.  Evaluation with endothelial nitric oxide synthase (eNOS) immunoreactivity of the protective role of astaxanthin on hepatorenal injury of remote organs caused by ischaemia reperfusion of the lower extremities.

Authors:  Ahmet Uyar; Turan Yaman
Journal:  Prz Gastroenterol       Date:  2019-10-09

Review 6.  Renal effects of levosimendan: a consensus report.

Authors:  Mehmet B Yilmaz; Elena Grossini; José C Silva Cardoso; István Édes; Francesco Fedele; Piero Pollesello; Matti Kivikko; Veli-Pekka Harjola; Julia Hasslacher; Alexandre Mebazaa; Andrea Morelli; Jos le Noble; Anders Oldner; Ignacio Oulego Erroz; John T Parissis; Alexander Parkhomenko; Gerhard Poelzl; Sebastian Rehberg; Sven-Erik Ricksten; Luís M Rodríguez Fernández; Markku Salmenperä; Mervyn Singer; Sascha Treskatsch; Bojan Vrtovec; Gerhard Wikström
Journal:  Cardiovasc Drugs Ther       Date:  2013-12       Impact factor: 3.727

7.  Effects of alprostadil and iloprost on renal, lung, and skeletal muscle injury following hindlimb ischemia-reperfusion injury in rats.

Authors:  Dilek Erer; Abdullah Özer; Hüseyin Demirtaş; İpek Işık Gönül; Halil Kara; Hande Arpacı; Faruk Metin Çomu; Gürsel Levent Oktar; Mustafa Arslan; Ayşegül Küçük
Journal:  Drug Des Devel Ther       Date:  2016-08-19       Impact factor: 4.162

8.  Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery: a meta-analysis and trial sequential analysis of randomized trials.

Authors:  Zhenhua Xing; Liang Tang; Pengfei Chen; Jiabing Huang; Xiaofan Peng; Xinqun Hu
Journal:  Sci Rep       Date:  2018-05-17       Impact factor: 4.379

9.  Assessment of the effects of levosimendan and thymoquinone on lung injury after myocardial ischemia reperfusion in rats.

Authors:  Şaban Cem Sezen; Aysegul Kucuk; Abdullah Özer; Yiğit Kılıç; Barış Mardin; Metin Alkan; Fatmanur Duruk Erkent; Mustafa Arslan; Yusuf Ünal; Gürsel Levent Oktar; Murat Tosun
Journal:  Drug Des Devel Ther       Date:  2018-05-22       Impact factor: 4.319

10.  Effects of Selenium and Melatonin on Ocular Ischemic Syndrome.

Authors:  Hande Hüsniye Telek
Journal:  Biomed Res Int       Date:  2019-12-06       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.